Serum leucine-rich alpha-2 glycoprotein levels for predicting ultrasonographic findings in intestinal lesion of patients with Crohn's disease in clinical remission (SAPICL study)

Serum leucine-rich alpha-2 glycoprotein levels for predicting ultrasonographic findings in intestinal lesion of patients with Crohn's disease in clinical remission (SAPICL study) - SAPICL study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049228

Enrollment

100

Registered

2022-10-17

Start date

2022-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CD patients of all ages who had evaluated LRG levels and received intestinal ultrasonography on the same day between September 2020 and August 2022.In case that LRG measurement and intestinal ultrasonography were performed multiple times within the applicable period, the first time of the investigation were recruited.

Exclusion criteria

Exclusion criteria: (1) Patients whose data of Harvey-Bradshaw Index (HBI) could not be evaluated from medical records. (2) Patients whose HBI is 5 or above. (3) Patients who had underwent intestinal resection.

Design outcomes

Primary

Measure	Time frame
Determining the cutoff value of LRG levels for predicting positive bowel wall thickness (BWT), focally or extensively disrupted bowel wall echo patterns, and respective superb micro-vascular imaging(SMI) grades and calculating the sensitivity and specificity.	—

Secondary

Measure	Time frame
Comparison of the median LRG levels for the positive BWT, focally or extensively disrupted bowel wall echo patterns, and respective SMI grades. Proportion of patients with positive BWT, those with focally or extensively disrupted bowel wall echo pattern, and those with respective SMI grades, respectively stratified by cutoff value of LRG levels. Proportion of patients with focally or extensively disrupted bowel wall echo pattern and that with respective SMI grades, respectively stratified by BWT. Evaluating the background factors related to the LRG levels. Determining the LRG cutoff value stratified by the background factors related to LRG levels and calculating the sensitivity and specificity. Etc	—

Measure

Time frame

Comparison of the median LRG levels for the positive BWT, focally or extensively disrupted bowel wall echo patterns, and respective SMI grades. Proportion of patients with positive BWT, those with focally or extensively disrupted bowel wall echo pattern, and those with respective SMI grades, respectively stratified by cutoff value of LRG levels. Proportion of patients with focally or extensively disrupted bowel wall echo pattern and that with respective SMI grades, respectively stratified by BWT. Evaluating the background factors related to the LRG levels. Determining the LRG cutoff value stratified by the background factors related to LRG levels and calculating the sensitivity and specificity. Etc

—

Countries

Japan

Contacts

Public ContactHiroki Tanaka

Sapporo IBD Clinic N/A

hirokit@mtc.biglobe.ne.jp011-213-0397

Outcome results